EUVIMEDEUVIMED entdecken
Crossref

Safety of Inhaled Tobramycin for Pseudomonas Eradication in People With Cystic Fibrosis Less Than 1 Year of Age

Daniel Riggsbee, Rebecca S Pettit iD

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Daniel Riggsbee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Riley Hospital for Children at IU Health, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Tobramycin, Cystic Fibrosis, Pseudomonas Infections, Anti-Bacterial Agents. Die Arbeit nennt 19 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inhaled tobramycin solution is recommended for eradication treatment of Pseudomonas aeruginosa (PA) infections in people with cystic fibrosis (PwCF). However, there is limited information on the safety of inhaled tobramycin in PwCF less than 1 year old and no studies primarily analyzing the safety of the 300 mg inhaled solution. The objective of this study was to compare the incidence of adverse drug events (ADE) of inhaled tobramycin in PwCF less than 1 year old to PwCF ages 1 year to 18 years old.

Methods

This retrospective analysis evaluated the incidence of inhaled tobramycin ADEs in PwCF ages 14 days to 18 years with CF between January 01, 2008 to January 01, 2022. PwCF less than 1 year of age (infant group) were matched based on genotype in a 1:3 ratio with a PwCF at least a year old to 18 year‐old (children group).

Results

Forty‐eight patients were included (infant group: 12, children group: 36). Median (IQR) age was 0.48 years (0.2–0.7) and 4.7 years (2.3–10) in infant group and children group respectively ( p < 0.05). There were 5 (41.7%) ADE in the infant group and 3 (8.3%) in the children group ( p = 0.016). When cough was removed there was no significant difference between the two groups [2 (16.7%) vs. 1 (2.7%), p = 0.15]. There was no difference in treatment failure [3 (25%) vs. 7 (19.4%), p = 0.68].

Conclusions

This study found a higher incidence of inhaled tobramycin ADE in infants compared to children. These results show a low risk of ADE outside of cough, indicating that inhaled tobramycin may be safely used in this age group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TobramycinCystic FibrosisPseudomonas InfectionsAnti-Bacterial AgentsHumansAdministration, InhalationRetrospective StudiesInfantMaleFemaleAdolescentChildChild, PreschoolPseudomonas aeruginosaInfant, Newborn

Stichwörter der Autor:innen

adverse eventscystic fibrosistobramycin

Substanzen

TobramycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Riley Hospital for Children at IU Health, Indianapolis, Indiana, USA.

ORCID-Profile: Rebecca S Pettit

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Riggsbee, D., & Pettit, R. S. (2025). Safety of Inhaled Tobramycin for Pseudomonas Eradication in People With Cystic Fibrosis Less Than 1 Year of Age. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71162

Vancouver

Riggsbee D, Pettit RS. Safety of Inhaled Tobramycin for Pseudomonas Eradication in People With Cystic Fibrosis Less Than 1 Year of Age. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71162

BibTeX
@article{Riggsbee2025,
  author = {Riggsbee, Daniel and Pettit, Rebecca S},
  title = {Safety of Inhaled Tobramycin for Pseudomonas Eradication in People With Cystic Fibrosis Less Than 1 Year of Age},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71162}
}
Kostenlos starten →